You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國醫療集團(08225.HK)成立生物樣品檢測實驗室並與妙手醫生共同馳援新冠患者
格隆匯 02-13 06:58

格隆匯2月13日丨中國醫療集團(08225.HK)公佈,公司成立生物樣品檢測實驗室並在配置Waters UPLC-MS/MS.Xevo TQS正式對外開放,該實驗室主要服務臨牀研究尤其是抗病毒藥物的臨牀研究實驗,管理層相信這將增強公司在新臨牀研究的競爭力。

公告稱,公司與著名互聯網醫療機構妙手醫生達成戰略合作,共同遠端馳援新冠狀病毒肺炎患者等。公司將繼續利用我司在腦科學、變態反應學和病毒傳染等領域的臨牀研究及醫學大資料的競爭能力與更多醫療機構合作。

據悉,公司的關聯公司收到福建省藥監局關於申請利托那韋(Ritonavir)口服液藥品復產上市的指導覆函,公司預計在這次疫情當中將會作為國內第一家生產上市企業,且利托那韋(Ritonavir)口服液有望成為本次疫情的戰略儲備物資之一。由於公司生產關聯公司及其他製藥企業依賴集團在該領域的臨牀研發服務能力,因此公司預計在該領域將會取得更多醫學研究和臨牀服務收入。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account